Please provide your email address to receive an email when new articles are posted on . Anti-neutrophil cytoplasmic antibodies are linked to an increased prevalence of interstitial lung disease and ...
Risk factors for relapse after reinduction treatment with rituximab in patients with antineutrophil cytoplasmic ...
Serum CXCL6 was higher in ANCA-associated vasculitis with interstitial lung disease and independently predicted ILD progression, suggesting a blood biomarker to identify AAV-ILD and monitor risk.
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
MedPage Today on MSN
Quality of life an ongoing struggle in ANCA-associated vasculitis
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comes with a heavy quality-of-life burden that doesn't ...
Antineutrophil cytoplasmic autoantibodies (ANCAs) are associated with and probably cause pauci-immune systemic necrotizing small-vessel vasculitis and glomerulonephritis ANCAs specific for proteinase ...
Credit: Getty Images Men have higher serum creatinine levels at presentation and are more likely to start dialysis within 4 weeks of diagnosis compared with women. PHILADELPHIA—Investigators who ...
ChemoCentryx, Inc. (NASDAQ: CCXI) shares more than tripled on Tuesday after the firm, in conjunction with Vifor Fresenius Medical Care Renal Pharma, announced positive topline data from its late-stage ...
Mycophenolate mofetil (CellCept) was as effective as cyclophosphamide for remission induction in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Japanese researchers reported. In a ...
US regulators approved avacopan (Tavneos) for a rare immune disorder after receiving additional information to address concerns raised about the drug that were previously discussed at a public meeting ...
ST. GALLEN, Switzerland & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ:CCXI) today announced positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback